Vanguard Portfolio Management
ADCT icon

Vanguard Portfolio Management’s ADC Therapeutics ADCT Stock Holding History

Vanguard Portfolio Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$960K Sell
897,092
-136,185
-13% -$397K ﹤0.01% 2973
2026
Q1 		$3.87M Buy
+1,033,277
New +$4.07M ﹤0.01% 2404

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management's ADCT Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its ADC Therapeutics (ADCT) stake by 13% in Q2 2026, selling an estimated $397K and leaving 897,092 shares worth $960K. The position accounts for ﹤0.01% of the portfolio, ranked #2973.

Vanguard Portfolio Management first reported a position in ADCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.87M in Q1 2026. 104 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Vanguard Portfolio Management held 897,092 shares of ADC Therapeutics worth $960K as of Q2 2026.
  • Vanguard Portfolio Management sold 136,185 ADC Therapeutics shares in Q2 2026, an estimated $397K.
  • ADC Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2973 holding.
  • Vanguard Portfolio Management first reported a position in ADC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's ADC Therapeutics position peaked at $3.87M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.